Clinical trials: Neoplasms, Pharyngeal
Laryngeal Cancer, Hypopharynx Cancer
Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma
The aim of this study is to define whether combination of induction chemotherapy and PD-1 inhibitor (Toripalimab) improve the rate of larynx preservation, for patients with resectable laryngeal/hypopharyngeal carcinoma.
- Conditions
- Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms
- Trial name
- INSIGHT (NCT04995120)
- Testing
- chemotherapy TP regimen combined with Toripalimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Fudan University
Nasopharyngeal Neoplasms
Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families
In an effort to identify genetic factors linked to the development of nasopharyngeal cancer (NPC), the researchers identified and sampled 2,394 individuals from Taiwanese families in which two or more relatives had been diagnosed…
- Trial name
- NCT00393224
- Where
- China
- Volunteers
- 952 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Neoplasms, Carcinoma, Squamous Cell
Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)
To test the therapeutic ratio of accelerated radiotherapy and/or chemotherapy on locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT00563862
- Testing
- Conventional RT, Accelerated RT, Cisplatin
- Where
- 5 sites in China
- Volunteers
- 465 people
- Sponsor
- Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
This study is a multicenter, randomized, controlled phase III clinical trial aiming to investigate the efficacy and safety of Becotatug Vedotin induction therapy followed by concurrent chemoradiotherapy (CCRT) combined with…
- Trial name
- NCT07459296
- Testing
- Becotatug Vedotin, Sintilimab, Cisplatin
- Where
- China
- Volunteers
- 266 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma, Chemotherapy
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that concurrent and adjuvant PD-1 treatment added to concurrent chemo-radiotherapy could further decrease the rate of disease progression and…
- Conditions
- Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
- Trial name
- NCT04453813
- Testing
- Toripalimab plus concurrent chemo-radiotherapy, Concurrent chemo-radiotherapy
- Where
- 6 sites in China
- Volunteers
- 226 people
- Sponsor
- Sun Yat-sen University
Constriction, Pathological
Fully Coated, Removable, Self-expanding Oesophageal Stents for Preventing Strictures Following Complete Barretts Excision.
The purpose of this study is to investigate whether preventative placement of a removable oesophageal stent reduces the rate of scar tissue, or stricture formation after removing the precancerous or early cancerous Barrett's…
- Trial name
- CBE-001-SEOS (NCT01554280)
- Testing
- Fully coated, removable , self-expanding oesophageal stent
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Professor Michael Bourke
Nasopharyngeal Carcinoma
Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
This study aims to evaluate the efficacy and safety of the TPC regimen (nab-paclitaxel, cisplatin, and capecitabine) combined with apatinib and camrelizumab versus the GP regimen (gemcitabine and cisplatin) combined with…
- Trial name
- NCT06438627
- Testing
- TPC combined with Apatinib and Camrelizumab, GP Combined With Camrelizumab
- Where
- 2 sites in China
- Volunteers
- 164 people
- Sponsor
- XIANG YANQUN
Oral Cavity Cancer, Dysphagia
Dysphagia and Quality of Life in Patients With Oral Squamous Cell Carcinoma Before and After Treatment
While the group of oral cavity cancer (OCC) survivors continue to increase, surgeons and oncologist intensify their search for improved treatment and rehabilitation methods to reduce the morbidity of management without…
- Conditions
- Oral Cavity Cancer, Dysphagia, Quality of Life
- Trial name
- NCT06407570
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Nasopharyngeal Carcinoma, Radiotherapy
Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that radiotherapy with reduced dose could significantly reduce the incidence of radiotherapy toxicities, improve the quality of life of…
- Conditions
- Nasopharyngeal Carcinoma, Radiotherapy, Chemotherapy
- Trial name
- NCT04448522
- Testing
- reduced dosage IMRT, conventional dosage IMRT
- Where
- 6 sites in China, Singapore
- Volunteers
- 508 people
- Sponsor
- Sun Yat-sen University
Bladder Cancer, Glioma
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, [64Cu]CM500 and [68Ga]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission…
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
- Trial name
- NCT07781852
- Testing
- [64Cu]CM500, [68Ga]CM500, PET/MR
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumina Pharmaceuticals Inc
Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement (recurrent) and/or has spread to other parts of the body (metastatic).
- Conditions
- Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7
- Trial name
- NCT02339558
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- 19 sites in United States, China and 1 more
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of head and neck cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005647
- Testing
- paclitaxel, semaxanib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
Oropharyngeal Cancers, Biomarker in Early Diagnosis
Active MMP-8 in Oral Fluid for the Detection of Oral and Oropharyngeal Cancer
The goal of this observational study is to evaluate whether the active-matrix metalloproteinase-8 (aMMP-8) mouth-rinse test can help detect oral and oropharyngeal cancers.
- Conditions
- Oropharyngeal Cancers, Biomarker in Early Diagnosis, Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Periodontal Diseases
- Trial name
- NCT06701058
- Where
- Finland
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Oropharyngeal Cancer
Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy
Open-label, interventional, multicentric, randomized, phase III study. Cancer studied is the oropharyngeal cancer. Study is composed by 2 arms of subjects: prophylactic or reactive percutaneous endoscopic gastrostomy tube…
- Trial name
- SwallPEG (NCT04019548)
- Testing
- Percutaneous Endoscopic Gastrotomy tube placement, Cisplatin injection, Radiotherapy
- Where
- 2 sites in Belgium
- Volunteers
- 110 people
- Sponsor
- Jules Bordet Institute
Nasopharyngeal Carcinoma (NPC)
Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
To evaluate the efficacy and safety of neoadjuvant and adjuvant Sintilimab combined with chemoradiotherapy versus chemoradiotherapy alone in stage TanyN3M0 nasopharyngeal carcinoma.
- Trial name
- NCT06680115
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma
Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
In this multicenter, prospective, randomized, controlled, non-inferiority Phase III clinical trial, treatment-naïve patients with nasopharyngeal carcinoma (NPC) without metastasis will be enrolled for curative radiotherapy.
- Trial name
- OART (NCT06516133)
- Testing
- Intensity modulated radiation therapy (IMRT) with conventional planning target volume (PTV) margin and without online adaptive radiotherapy, Chemotherapy, Intensity modulated radiation therapy (IMRT) with smaller planning target volume (PTV) margin and online adaptive radiotherapy
- Where
- China
- Volunteers
- 494 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)
Patients have a type of cancer called nasopharyngeal carcinoma (NPC) which has either come back, not gone away or is at high risk for coming back after the best treatment we know for this disease.
- Trial name
- NATELLA (NCT00516087)
- Testing
- Genetically modified CTLs
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Baylor College of Medicine
Advanced Malignant Neoplasm, Castleman Disease
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body…
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease
- Trial name
- NCT01552434
- Testing
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Neoplasms, Deglutition Disorders
EMST in Patients Undergoing CRT for HNCA
This study is a randomized trial examining the impact of expiratory muscle strength training (EMST) on maintenance of safe and efficient oropharyngeal swallow function in persons with cancer of the head and neck (HNCA) undergoing…
- Trial name
- NCT03916809
- Testing
- EMST
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Milwaukee
Head And Neck Cancer
Testing Accountability in Patient Adherence
The goal of this research study is to look for factors that influence whether or not head and neck cancer patients follow the swallowing exercises that they are asked to perform while receiving radiation treatment.
- Trial name
- NCT01844557
- Testing
- Swallowing Exercises, Symptom Inventory, Questionnaires
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.